BioNTech (NASDAQ:BNTX) Earns "Buy" Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioNTech (NASDAQ:BNTX - Free Report) in a research note released on Monday, Benzinga reports. The brokerage currently has a $113.00 price objective on the stock.

Several other research analysts have also recently issued reports on BNTX. HSBC raised BioNTech from a hold rating to a buy rating in a research report on Friday, August 2nd. BMO Capital Markets dropped their target price on BioNTech from $123.00 to $122.00 and set an outperform rating for the company in a report on Tuesday, May 7th. JPMorgan Chase & Co. cut their price objective on BioNTech from $94.00 to $91.00 and set an underweight rating on the stock in a research report on Thursday. TD Cowen dropped their price target on BioNTech from $98.00 to $85.00 and set a hold rating on the stock in a research report on Tuesday, August 6th. Finally, Evercore ISI assumed coverage on BioNTech in a research note on Tuesday, May 14th. They issued an inline rating and a $100.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus target price of $109.09.

BioNTech Stock Performance

BNTX traded up $4.74 on Monday, hitting $89.93. The company's stock had a trading volume of 1,570,587 shares, compared to its average volume of 705,310. The company's 50 day simple moving average is $84.52 and its 200-day simple moving average is $89.66. The firm has a market cap of $21.38 billion, a P/E ratio of 179.86 and a beta of 0.23. The company has a quick ratio of 11.16, a current ratio of 11.38 and a debt-to-equity ratio of 0.01. BioNTech has a 12 month low of $76.53 and a 12 month high of $125.83.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing analysts' consensus estimates of ($2.02) by ($1.34). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The company had revenue of $128.70 million for the quarter, compared to analysts' expectations of $134.98 million. During the same period last year, the company posted ($0.86) EPS. The business's revenue for the quarter was down 23.3% compared to the same quarter last year. Analysts forecast that BioNTech will post -2.04 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BNTX. GAMMA Investing LLC lifted its stake in BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company's stock worth $25,000 after acquiring an additional 150 shares in the last quarter. CWM LLC lifted its holdings in BioNTech by 657.6% during the 4th quarter. CWM LLC now owns 250 shares of the company's stock valued at $26,000 after purchasing an additional 217 shares during the last quarter. Frazier Financial Advisors LLC bought a new position in BioNTech in the 4th quarter valued at $30,000. First Horizon Advisors Inc. acquired a new position in BioNTech during the 4th quarter worth about $38,000. Finally, Covestor Ltd lifted its holdings in BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company's stock worth $38,000 after buying an additional 133 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.